Organization
Abbott GmbH & Co KG, Ludwigshafen, Germany
3 abstracts
Abstract
ADALIMUMAB TREATMENT MAINTAINS EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) — 2-YEAR RESULTS FROM ATLASOrg: University Hospital Maastricht, Maastricht, Netherlands, Denver Arthritis Clinic, Denver, United States, Charite Universitatsmedizin Berlin, Berlin, Germany, Center for Clinical Research, Duncansville, United States, VU Medical Centre, Amsterdam, Netherlands,
Abstract
ACTIVE MRI LESIONS PREDICT CLINICAL RESPONSE BUT NOT TIME UNTIL RELAPSE FOR PATIENTS WITH ACTIVE AXIAL NON-RADIOGRAPHIC SPONDYLOARTHRITIS —52-WEEK RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL Org: Charité, University Medicine Berlin, Berlin, Centre of Rheumatology, Herne, German Rheumatism Research Centre, Berlin, Germany, Abbott Laboratories, Parsippany, NJ, United States, Abbott GmbH & Co KG, Ludwigshafen, Germany,
Abstract
ADALIMUMAB IS EFFECTIVE IN REDUCING SIGNS AND SYMPTOMS IN ANKYLOSING SPONDYLITIS PATIENTS WITH TOTAL SPINAL ANKYLOSIS – RESULTS FROM ATLASOrg: University Hospital Maastricht, Maastricht, Netherlands, Denver Arthritis Clinic, Denver, United States, Ruhr University Bochum, Bochum, Germany, Clinical Research Center of Reading, W. Reading, United States, Hospital Monte Naranco, Oviedo-Asturias, Spain,